title: A randomized controlled study of modified cobratoxin in adrenomyeloneuropathy.
abstract: Adrenomyeloneuropathy is a peroxisomal disorder that causes demyelination, with no proven therapy. Oral modified cobratoxin was assessed in a double-blind, randomized, crossover study of eight patients. Treatment was well tolerated. There were no significant improvements with therapy. The authors do not confirm previous anecdotal reports of dramatic improvement with modified cobratoxin.
authors.affiliation: Charles Dent Metabolic Unit, National Hospital for Neurology and Neurosurgery, Queen Square, London, UK. helen.mundy@uclh.org
authors.forename: H R
authors.initials: HR
authors.lastname: Mundy
authors.forename: S J
authors.initials: SJ
authors.lastname: Jones
authors.forename: J C
authors.initials: JC
authors.lastname: Hobart
authors.forename: M G
authors.initials: MG
authors.lastname: Hanna
authors.forename: P J
authors.initials: PJ
authors.lastname: Lee
mesh_terms: D000326:Adrenoleukodystrophy / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D003039:Cobra Neurotoxin Proteins / Q000627:therapeutic use*; D004311:Double-Blind Method; D005071:Evoked Potentials; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012720:Severity of Illness Index; D017211:Treatment Failure
chemical_list: D003039:Cobra Neurotoxin Proteins